Arvinas

-$1.17 (-1.17%) As of 6:13 PM UTC today

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.

About ARVN

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.

CEO
John G. Houston
Employees
179
Headquarters
New Haven, Connecticut
Founded
2013

ARVN Key Statistics

Market Cap
4.87B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
975.59K
High Today
$103.19
Low Today
$98.32
Open Price
$99.69
Volume
159.16K
52 Week High
$108.47
52 Week Low
$19.68

ARVN Earnings

-$0.99
-$0.66
-$0.33
$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
Expected Aug 17, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure